Wolwo Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 345 million yuan, an increase of 26.67%
According to the Zhitong Finance APP, Wolwo Pharma released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 853 million yuan, a year-on-year increase of 16.86%. The net profit attributable to shareholders of the listed company was 345 million yuan, a year-on-year increase of 26.67%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 340 million yuan, a year-on-year increase of 28.92%. The basic earnings per share were 0.6587 yuan
According to the Zhitong Finance APP, Wolwo Pharma (300357.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 853 million yuan, a year-on-year increase of 16.86%. The net profit attributable to shareholders of the listed company was 345 million yuan, a year-on-year increase of 26.67%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 340 million yuan, a year-on-year increase of 28.92%. The basic earnings per share were 0.6587 yuan
